Efficacy and safety of contezolid in the treatment of Gram-positive bacterial infections in patients with hematological malignancies: a retrospective study
European Journal of Clinical Microbiology & Infectious Diseases · 2025
DOI: 10.1007/s10096-025-05280-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2025. Verfasst von Ruihua Mi und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Gram-Positive Bacterial Infections, Anti-Bacterial Agents, Oxazolidinones. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Henan Province, Henan Province Outstanding Young and Middle-aged Talents Cultivation Project for Health Science and Technology Innovation, China, Investigator-initiated Clinical Tial and Transformation of Scientific Achievements, Henan CancerHospital.
Abstract (Originalsprache)
PURPOSE: Contezolid, an oxazolidinone antibiotic, is recognized for its comparable antimicrobial activity to linezolid, with a distinct advantage of reduced hematological toxicity. This retrospective analysis aims to evaluate the safety and efficacy profile of contezolid in the treatment of Gram-positive bacterial infections (GPI) in hematological patients. METHODS: A retrospective analysis was conducted on adult hematological patients with confirmed or suspected GPI who received contezolid for at least three days following chemotherapy or hematopoietic stem cell transplantation (HSCT) at Henan Cancer Hospital between April 2022 and June 2024. Comprehensive data collection included demographic variables, treatment protocols, infection profiles, microbiological data, and clinical outcomes. RESULTS: The study included 132 patients (47.5 ± 18.0 years), 61.4% male. Treatment strategies for hematological malignancies included combination chemotherapy with targeted therapy (41.7%), chemotherapy alone (37.9%), and HSCT (20.5%). 60.6% had febrile neutropenia. More than half of the infections occurred within one month after treatment, predominantly affecting the lungs and skin/soft tissue. Two patients had concurrent bloodstream infections (BSI) prior to receiving contezolid treatment. The median contezolid treatment was 12 days, 72.7% had it as initial treatment. The rationale for contezolid utilization includes complicated skin and soft-tissue infections (cSSTI), prior treatment failure, adverse reactions, and contraindications. Clinical effective rate was 70.6% (95% CI: 62.7% - 78.5%), with 64.4% (95% CI: 52.2% - 76.6%) in pneumonia, 74.6% (95% CI: 63.0% - 86.1%) in skin or soft tissue infections, and 69.3% (95% CI: 58.9% - 79.8%) in febrile neutropenia. Seventeen patients (12.9%) had adverse events. Twelve had new-onset/aggravated nausea or epigastric discomfort, and seven had vomiting; these may relate to contezolid. No contezolid-related hematological adverse events, optic or peripheral neuropathy were observed. CONCLUSIONS: Contezolid seems promising for these patients, but large-scale prospective studies are needed for confirmation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
- The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. xudongwei@zzu.edu.cn.
Förderung
- Natural Science Foundation of Henan Province
- Henan Province Outstanding Young and Middle-aged Talents Cultivation Project for Health Science and Technology Innovation, China
- Investigator-initiated Clinical Tial and Transformation of Scientific Achievements, Henan CancerHospital
- National Natural Science Foundation of China
Zitieren
APA
Mi, R., Chang, L., Chen, L., Wang, L., Ma, Y., Liu, J., Li, D., & Wei, X. (2025). Efficacy and safety of contezolid in the treatment of Gram-positive bacterial infections in patients with hematological malignancies: a retrospective study. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-025-05280-9
Vancouver
Mi R, Chang L, Chen L, Wang L, Ma Y, Liu J, et al. Efficacy and safety of contezolid in the treatment of Gram-positive bacterial infections in patients with hematological malignancies: a retrospective study. European Journal of Clinical Microbiology & Infectious Diseases. 2025. doi:10.1007/s10096-025-05280-9
BibTeX
@article{Mi2025,
author = {Mi, Ruihua and Chang, Luyang and Chen, Lin and Wang, Lin and Ma, Yixuan and Liu, Jia and Li, Dongbei and Wei, Xudong},
title = {Efficacy and safety of contezolid in the treatment of Gram-positive bacterial infections in patients with hematological malignancies: a retrospective study},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2025},
doi = {10.1007/s10096-025-05280-9}
}
EUVIMED